Arbutus Biopharma (NASDAQ:ABUS) Upgraded at Zacks Investment Research

Share on StockTwits

Zacks Investment Research upgraded shares of Arbutus Biopharma (NASDAQ:ABUS) from a sell rating to a hold rating in a research report released on Monday, Zacks.com reports.

According to Zacks, “Arbutus Biopharma Corporation is a biopharmaceutical company which is focused on discovering, developing and commercializing a portfolio of drug candidates for chronic hepatitis B infection. The Company’s products include TKM-HBV, Cyclophilin Inhibitor-OCB-030, TLR9 Agonist (CYT-003), Capsid Assembly Inhibitors, Surface Antigen Secretion Inhibitors, STING Agonists, cccDNA Formation Inhibitors, cccDNA Epigenetic Modifiers, TKM-PLK1, GI-NET and ACC, HCC, TKM-Ebola, TKM-Ebola-Guinea, TKM-Marburg, TKM-HTG and TKM-ALDH which are in different clinical trial stage. Arbutus Biopharma Corp, formerly known as Tekmira Pharmaceuticals Corporation, is headquartered in Vancouver, BC. “

Other equities analysts also recently issued research reports about the company. B. Riley upped their price target on Arbutus Biopharma from $3.00 to $6.00 and gave the stock a buy rating in a research report on Thursday, January 9th. Echelon Wealth Partners downgraded Arbutus Biopharma from a hold rating to a sell rating in a research report on Friday, October 4th. Chardan Capital downgraded Arbutus Biopharma from a buy rating to a neutral rating in a research report on Friday, October 4th. Finally, ValuEngine raised Arbutus Biopharma from a hold rating to a buy rating in a research report on Friday, January 3rd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company’s stock. The stock has an average rating of Hold and an average price target of $4.25.

Shares of ABUS opened at $3.07 on Monday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 10.70 and a current ratio of 10.70. The stock has a 50 day simple moving average of $2.54 and a 200 day simple moving average of $1.78. Arbutus Biopharma has a 52-week low of $0.82 and a 52-week high of $4.75. The firm has a market capitalization of $186.34 million, a PE ratio of -3.01 and a beta of 1.99.

Arbutus Biopharma (NASDAQ:ABUS) last issued its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.11) by ($0.22). Arbutus Biopharma had a negative net margin of 2,416.39% and a negative return on equity of 298.87%. The business had revenue of $3.10 million during the quarter, compared to analyst estimates of $9.85 million. Equities research analysts predict that Arbutus Biopharma will post -1.22 EPS for the current fiscal year.

A number of large investors have recently added to or reduced their stakes in the business. Jacobs Levy Equity Management Inc. boosted its position in Arbutus Biopharma by 40.4% during the 2nd quarter. Jacobs Levy Equity Management Inc. now owns 30,593 shares of the biopharmaceutical company’s stock worth $64,000 after acquiring an additional 8,797 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. boosted its holdings in shares of Arbutus Biopharma by 0.5% in the 2nd quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,774,915 shares of the biopharmaceutical company’s stock valued at $3,692,000 after buying an additional 9,500 shares during the last quarter. Tower Research Capital LLC TRC boosted its holdings in shares of Arbutus Biopharma by 710.8% in the 3rd quarter. Tower Research Capital LLC TRC now owns 38,789 shares of the biopharmaceutical company’s stock valued at $59,000 after buying an additional 34,005 shares during the last quarter. A.R.T. Advisors LLC acquired a new stake in shares of Arbutus Biopharma in the 2nd quarter valued at approximately $74,000. Finally, Millennium Management LLC boosted its holdings in shares of Arbutus Biopharma by 75.1% in the 3rd quarter. Millennium Management LLC now owns 356,066 shares of the biopharmaceutical company’s stock valued at $543,000 after buying an additional 152,714 shares during the last quarter. 30.75% of the stock is owned by hedge funds and other institutional investors.

About Arbutus Biopharma

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in Canada and the United States. Its HBV product pipeline consists of AB-506, a capsid inhibitor that has shown improved potency and pharmacokinetics over its first generation capsid inhibitor; and AB-423, which is in pre-clinical studies.

Featured Article: How to Invest in an Index Fund

Get a free copy of the Zacks research report on Arbutus Biopharma (ABUS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

DORCHESTER WEALTH MANAGEMENT Co Lowers Stake in Verizon Communications Inc.
DORCHESTER WEALTH MANAGEMENT Co Lowers Stake in Verizon Communications Inc.
BLB&B Advisors LLC Has $10.25 Million Holdings in Exxon Mobil Co.
BLB&B Advisors LLC Has $10.25 Million Holdings in Exxon Mobil Co.
BLB&B Advisors LLC Sells 1,070 Shares of SPDR S&P 500 ETF Trust
BLB&B Advisors LLC Sells 1,070 Shares of SPDR S&P 500 ETF Trust
Procter & Gamble Co  Shares Purchased by DORCHESTER WEALTH MANAGEMENT Co
Procter & Gamble Co Shares Purchased by DORCHESTER WEALTH MANAGEMENT Co
Verizon Communications Inc.  Shares Purchased by Candriam Luxembourg S.C.A.
Verizon Communications Inc. Shares Purchased by Candriam Luxembourg S.C.A.
DORCHESTER WEALTH MANAGEMENT Co Acquires 440 Shares of Pfizer Inc.
DORCHESTER WEALTH MANAGEMENT Co Acquires 440 Shares of Pfizer Inc.


© 2006-2020 Ticker Report